Mariia Serhiivna Matvieienko

Mariia Serhiivna Matvieienko

Auto-generated profile, based on publicly available information

Mariia Serhiivna Matvieienko

V.N. Karazin Kharkiv National University of the Ministry of Education and Science of Ukraine, Kharkiv, Ukraine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Journal of Pain Research
Verified
Journal Article
Open access
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
TLTetiana Liadova
Tetiana Liadova
MMMariia Matvieienko
Mariia Matvieienko
RKRoman Komorovsky
Roman Komorovsky
SSSvitlana Smiyan
Svitlana Smiyan
VSVolodymyr Student
Volodymyr Student
Central sensitization explains the mismatch between structural damage or inflammation and pain intensity in chronic musculoskeletal diseases. It defines the phenotype of fibromyalgia and contributes to persistent pain in osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. To characterize the role of central sensitization in nociplastic pain in fibromyalgia, osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. A structured search of PubMed, Scopus, Web of Science, and Google Scholar (1990–2025) identified open-access, evidence-based publications addressing pain pathophysiology, diagnosis, and treatment in these conditions. Central sensitization manifests as hyperalgesia, allodynia, expanded receptive fields, and impaired endogenous pain inhibition. It predominates in fibromyalgia and contributes to persistent pain in osteoarthritis and rheumatoid arthritis that may not correlate with inflammation or structural damage. Screening tools such as the Widespread Pain Index and Symptom Severity Scale, together with quantitative sensory testing and algometry, help identify nociplastic pain features. Neuroimmune mechanisms, including microglial activation and imbalance between excitatory and inhibitory neurotransmission, may contribute to the mismatch between pain intensity and clinical findings. Chronic pain reflects inflammatory, mechanical, and nociplastic mechanisms in rheumatoid arthritis, osteoarthritis, and fibromyalgia, respectively. Recognition of central sensitization improves assessment and supports mechanism-based management.

28 June 2024 in Karazin Journal of Immunology
Verified
Journal Article
Open access
PDF file
MMM.S. Matvieienko
M.S. Matvieienko
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
ООО.B. Оleksiuk
О.B. Оleksiuk
Background. The World Health Organization has recognized sepsis as one of the global health priorities. Sepsis is defined as the development of life-threatening multiple organ dysfunction caused by an unregulated immune response of the body (systemic inflammatory response syndrome) to infection, which is the direct cause of death of critically ill patients in the intensive care unit. Despite advances in infusion resuscitation, antibiotic use, and organ support that have combined to reduce in-hospital mortality, patients with sepsis exhibit increased long-term morbidity and mortality. Many sepsis survivors suffer long-term physical and cognitive impairments and have a higher mortality rate than the general population. To date, several preclinical studies have identified mesenchymal stromal cells (MSCs) as a novel tool for sepsis therapy due to their ability to suppress the inflammatory response. Purpose – to give an assessment of the prospective study of the therapeutic effectiveness of MSC derivatives in sepsis. Materials and Methods. Publications were selected based on the databases PubMed, Clinical Key Elsevier, Cochrane Library, eBook Business Collection, and Google Scholar, which covered information on the therapeutic effects of exosomes obtained from MSCs in sepsis. At the first stage, literature sources were searched using key words: sepsis, extracellular vesicles, exosomes, mesenchymal stromal cells, acute respiratory distress syndrome, acute kidney injury, myocardial dysfunction, liver damage. At the second stage, summaries of articles were studied and publications that did not meet the research criteria were excluded. At the third stage, the full texts of the selected articles were studied for compliance with the criteria for inclusion in the literature list and research relevance. Results. Taking into account the key pathogenetic links of sepsis, the data on the therapeutic effectiveness of exosomes from MSCs in four leading sepsis syndromes – acute lung injury, kidney damage, cardiovascular disorders, and liver damage caused by sepsis – are described. Acute lung injury is the most common organ injury in patients with sepsis, increasing mortality to 40%. Exosomes are key effectors of pulmonary endothelial interactions with neighboring and circulating cells and mediators for modulating local immune thrombosis, inflammatory cell adhesion, and alveolar unit integrity. A number of experimental studies have demonstrated the effectiveness of using exosomes from MSCs in simulated acute lung injury in animals. Acute kidney injury (AKI) occurs in 20% of patients with sepsis, and cardiac involvement is a common disorder in patients with sepsis, and approximately 50% of patients with sepsis show signs of myocardial dysfunction. Inflammation and coagulation are critical components in sepsis, involving leukocytes, platelets, and vascular endothelial cells. Hepatoprotective activity of exosomes from MSCs has been demonstrated in a number of acute liver injuries, in particular those induced by tetrachloromethane, concanavalin A, and ischemia-reperfusion liver injury models. Conclusions. A number of studies have demonstrated that MSC-derived secretome exhibits therapeutic effects similar to those seen after MSC transplantation. Exosomes derived from both immune and non-immune cells play an important role in immune regulation, which can contribute to the pathology of many diseases by mediating immune stimulation or suppression. Exosomes obtained from MSCs have protective activity in the leading syndromes of sepsis – in acute lung injury, in kidney damage, in cardiovascular disorders and against the background of liver damage caused by sepsis.

30 April 2025 in The Journal of V. N. Karazin Kharkiv National University, Series "Medicine"
Verified
Journal Article
Open access
PDF file
МCМ.о. Chyzh
М.о. Chyzh
MMM.S. Matvieienko
M.S. Matvieienko
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
ТLТ.і. Liadova
Т.і. Liadova
RKRoman Komorovsky
Roman Komorovsky
TKT.V. Kozlova
T.V. Kozlova
Background. Myocardial disease typically involves pronounced oxidative stress, which contributes to cardiomyocyte damage, myocardial remodeling, and the development of heart failure. Current therapeutic approaches are not always capable of fully neutralizing the excessive production of free radicals; therefore, the search for new cardioprotective agents capable of correcting the imbalance between reactive oxygen species (ROS) and antioxidant mechanisms is highly relevant. Purpose – To investigate the cardioprotective activity of porcine heart cryoextract, particularly its effect on oxidative stress markers in cardiac tissue and blood serum using a rat model of adrenaline-induced myocardial dystrophy (AMD). Materials and Methods. The experiment was conducted on 84 outbred male rats divided into four groups (n = 21): intact animals; rats with AMD without treatment; rats with AMD that received intraperitoneal injections of heart cryoextract (50 µg of peptides/100 g of body weight) for 14 days; and rats with AMD treated with cordarone (10 mg/kg, intramuscularly) for 14 days. Levels of lipid peroxidation products were assessed: thiobarbituric acid reactive substances (TBARS) and diene conjugates in heart homogenates, and malondialdehyde (MDA) in blood serum on days 2, 7, and 14 after AMD induction. Results. AMD induction was associated with a significant increase in TBARS (+140.5%), MDA (+82.5%), and diene conjugates (+252.9%) compared to intact rats (p < 0.001). On day 2, the cryoextract reduced TBARS by 33.7% (p < 0.001), MDA by 11.0%, and diene conjugates by 16.7%, which was comparable to the effects of cordarone (30.3% and 6.4%, respectively; p > 0.05). During the 7–14 days of treatment, both agents maintained a significant reduction in oxidative stress markers, although MDA and diene conjugate levels did not reach the baseline values observed in intact animals. Conclusions. Porcine heart cryoextract demonstrated significant cardioprotective effects by correcting oxidative imbalance in a model of adrenaline-induced myocardial dystrophy and showed efficacy comparable to that of cordarone in reducing key markers of free radical oxidation. Heart cryoextract appears to be a promising agent in the pathogenetic treatment of AMD, aimed at lowering oxidative stress, stabilizing membranes, restoring antioxidant enzyme activity, and preserving redox homeostasis

1 January 2025
Verified
Book
Closed access
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
TLTetyana Ivanivna Liadova
Tetyana Ivanivna Liadova
MCMykola Oleksiiovych Chezh
Mykola Oleksiiovych Chezh
RKRoman Komorovsky
Roman Komorovsky
MMMariia Serhiivna Matvieienko
Mariia Serhiivna Matvieienko
HBHanna Heorhiyivna Babayeva
Hanna Heorhiyivna Babayeva
Монографія присвячена кардіопротекторній активності безклітинних кріоконсервованих біологічних засобів при серцево-судинних захворюваннях, таких як аутоімунний міокардит, кардіоміопатії та адреналінова міокардіодистрофія. Особлива увага приділяється механізмам дії кріоекстрактів плаценти, селезінки та серця, їх впливу на морфофункціональні зміни міокарда, антиоксидантно-прооксидантний гомеостаз, енергетичні процеси та вуглеводний обмін. Монографія висвітлює сучасні підходи до лікування серцево-судинних захворювань, демонструючи потенціал безклітинних біологічних препаратів для кардіопротекції та регенерації серця. Монографія буде корисною для широкого кола лікарів-клініцистів, зокрема кардіологів, а також фармакологів, біохіміків, патофізіологів та здобувачів вищої освіти медичного та фармацевтичного профілю. Таблиць – 56, рисунків – 35, бібліографія – 483 посилань. The monograph is dedicated to the cardioprotective activity of acellular cryopreserved biological agents in cardiovascular diseases such as autoimmune myocarditis, cardiomyopathies, and adrenaline-induced myocardial dystrophy. Special attention is given to the mechanisms of action of cryoextracts from placenta, spleen, and heart, their impact on morphofunctional changes in the myocardium, antioxidant-prooxidant homeostasis, energy processes, and carbohydrate metabolism. The monograph highlights modern approaches to the treatment of cardiovascular diseases, demonstrating the potential of acellular biological agents for cardioprotection and heart regeneration. This monograph will be useful for a wide range of clinicians, particularly cardiologists, as well as pharmacologists, biochemists, pathophysiologists, and students of medical and pharmaceutical education. Tables – 56, figures – 35, bibliography – 483 references.

25 June 2025 in Ukrainian journal of cardiovascular surgery
Verified
Journal Article
Open access
PDF file
MCMykola O. Chyzh
Mykola O. Chyzh
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
TLTetiana I. Liadova
Tetiana I. Liadova
MMMariia S. Matvieienko
Mariia S. Matvieienko
RKRoman Komorovsky
Roman Komorovsky
Metabolic injury to the myocardium during excessive adrenergic stimulation is primarily mediated by overstimulation of β-adrenergic receptors, resulting in a cascade of biochemical and structural changes that lead to myocardial toxicity. Aim. To investigate the effect of an extract derived from cryopreserved fragments of piglet hearts on glycogenolysis activity in cardiomyocytes, and to evaluate its potential therapeutic efficacy in a model of adrenaline-induced myocardial dystrophy. Materials and methods. The study was conducted on 84 non-linear male white rats. Adrenaline-induced myocardial dystrophy was modeled using a single subcutaneous injection of 0.18 % adrenaline tartrate at a dose of 5 mg/kg (according to the method of Markova). The experimental group received an intraperitoneal injection of the extract (peptide concentration 0.1 mg/ml, 50 μg per 100 g body weight) daily for 14 days. LDH activity was measured in blood serum using a spectrophotometric method. Lactate and pyruvate concentrations were determined spectrophotometrically in myocardial tissue homogenates collected post-mortem. Results. In the untreated group, adrenaline administration caused significant metabolic disturbances: increased LDH activity, elevated lactate levels, and reduced pyruvate concentrations, indicating a shift toward anaerobic glycolysis and myocardial hypoxia. Administration of the extract significantly reduced LDH activity and lactate concentrations, while increasing pyruvate levels and restoring the lactate/pyruvate ratio toward physiological values. These findings suggest a restoration of oxidative phosphorylation and improved energy metabolism in cardiomyocytes. Conclusions. The extract of cryopreserved piglet heart tissue demonstrates therapeutic potential as a metabolic modulator in the context of catecholamine-induced myocardial injury. Its ability to normalize lactate-pyruvate metabolism indicates its promise as a cardioprotective agent for correcting metabolic imbalances in myocardial dystrophy.

1 January 2025 in Eastern Ukrainian Medical Journal
Verified
Journal Article
Open access
PDF file
МCМ. О. Chyzh
М. О. Chyzh
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
ТLТ. І. Liadova
Т. І. Liadova
MMM. S. Matvieienko
M. S. Matvieienko
RKRoman Komorovsky
Roman Komorovsky
Background. Myocardiodystrophy represents a severe metabolic disturbance in the cardiac muscle, leading to structural and functional alterations in cardiomyocytes and impaired cardiac performance. One of the key pathological mechanisms is the disruption of glycogenolysis, which negatively impacts myocardial energy metabolism. Considering the critical importance of maintaining energy homeostasis in the heart, biologically active substances derived from cryopreserved xenogeneic heart fragments emerge as a promising therapeutic avenue. Objective. To investigate the effects of an extract from cryopreserved piglet heart fragments on glycogenolysis activity in cardiomyocytes and its potential therapeutic impact in a model of adrenaline-induced myocardiodystrophy (AMD). Methods. The study involved 84 outbred male rats (250–300 g) maintained under standard vivarium conditions. AMD was induced using a single subcutaneous injection of 0.18% adrenaline tartrate solution at a dose of 5 mg/kg. The experimental group received daily intraperitoneal injections of the extract at 50 µg of peptides per 100 g of body weight for 14 days. The control group was administered an equivalent volume of 0.9% sodium chloride solution. Amiodarone (10 mg/kg, intramuscularly) served as a reference drug. Heart tissue homogenates were analyzed post-decapitation. Glycogen content was measured using the glucose oxidase method, and glucose-6-phosphate (G-6-P) levels were determined spectrophotometrically using the hexokinase method. Results. On day 2, rats treated with the extract showed a glycogen level of 3.1±0.14 mg/g (95% CI: 2.8–3.4), a 48.3% increase compared to controls (p=0.007). In the amiodarone group, glycogen reached 4.2±0.06 mg/g (95% CI: 4.1–4.3), a 99.3% increase over controls (p<0.001), yet lower than that in the extract group. By day 14, extract-treated rats exhibited a glycogen level of 8.0±0.30 mg/g (95% CI: 7.4–8.6), up 156.4% from day 2 (p=0.01) and 61.1% from day 7 (p=0.01). On day 14, G-6-P levels in the control group were 0.79 [0.77–0.86] µmol/g, representing a 75.6% increase from day 2 (p=0.01) and 38.6% from day 7 (p=0.05). In the extract group, G-6-P levels reached 0.80 [0.79–0.81] µmol/g, a 56.9% rise from day 2 (p=0.01) and 25.0% from day 7 (p=0.01). The amiodarone group showed G-6-P levels of 0.82 [0.81–0.82] µmol/g, a 57.7% increase from day 2 (p=0.01) and 24.2% from day 7 (p=0.01). Conclusions. The extract from cryopreserved piglet heart fragments demonstrated a significant corrective effect on carbohydrate metabolism disorders in the myocardium of rats with adrenaline-induced myocardiodystrophy. This includes normalization of glycogen and G-6-P levels, highlighting its potential as a therapeutic agent for myocardial ischemic and hypoxic conditions.